Tolemy Bio develops AI-driven tools to design, optimize, and control cell culture processes for advanced therapies.
Tolemy Bio has raised $1.6M in total funding. The most recent round was Pre-Seed. The last funding was announced in May 2026.
Tolemy Bio's investors include Marcel Hedman, David Ola, JME Ventures, Big Sur Ventures, Norrsken Evolve.
Tolemy Bio is headquartered in Cambridge, United Kingdom.
Tolemy Bio develops AI-driven tools to design, optimize, and control cell culture processes for advanced therapies.
Tolemy Bio is at the Pre-Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Tolemy Bio — Funding & Investors." VCBacked, May 12, 2026, https://www.vcbacked.co/company/tolemy-bio. Accessed October 1, 2026.
VCBacked. (2026). Tolemy Bio — Funding & Investors. Retrieved October 1, 2026, from https://www.vcbacked.co/company/tolemy-bio
{{cite web |title=Tolemy Bio — Funding & Investors |url=https://www.vcbacked.co/company/tolemy-bio |website=VCBacked |access-date=October 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated